A randomised comparison of bicalutamide ('Casodex') 150 mg versus placebo as immediate therapy either alone or as adjuvant to standard care for early non-metastatic prostate cancer first report from the scandinavian prostatic cancer group study no. 6

European Urology

Volumn 42, Issue 3, 2002, Pages 204-211

  Iversen, P ^a   Tammela, T L J ^b   Vaage, S ^c   Lukkarinen, O ^d   Lodding, P ^e   Bull Njaa, T ^f   Viitanen, J ^g   Hoisaeter, P ^h   Lundmo, P ⁱ   Rasmussen, F ^a   Johansson, J E ^j   Persson, B E ^k   Carroll, K ^l  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TAMPERE UNIVERSITY HOSPITAL   (Finland)

^c STAVANGER UNIVERSITY HOSPITAL   (Norway)

^d OULU UNIVERSITY HOSPITAL   (Finland)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f AKER UNIVERSITY HOSPITAL   (Norway)

^g NORTH KARELIA CENTRAL HOSPITAL   (Finland)

^h HAUKELAND UNIVERSITY HOSPITAL   (Norway)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

^k ASTRAZENECA R AND D   (Sweden)

^l ASTRAZENECA   (United Kingdom)

more..

Author keywords

Bicalutamide; Disease progression; Early prostate cancer; Sexual function; Standard care

Indexed keywords

BICALUTAMIDE; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BRONCHITIS; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FOLLOW UP; GYNECOMASTIA; HEMATURIA; HUMAN; HYPERTENSION; IMPOTENCE; MAJOR CLINICAL STUDY; MALE; MASTALGIA; PAIN; PELVIS PAIN SYNDROME; PNEUMONIA; PRIORITY JOURNAL; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; URINARY TRACT DISEASE; URINARY TRACT INFECTION; URINE RETENTION;

AGED; AGED, 80 AND OVER; ANILIDES; ANTINEOPLASTIC AGENTS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DOUBLE-BLIND METHOD; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; SEXUAL BEHAVIOR; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 0036715464     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0302-2838(02)00311-1     Document Type: Article

References (19)

1. The National Cancer Data Base report on prostate carcinoma after the peak in incidence rates in the US
2. Natural history of progression after PSA elevation following radical prostatectomy
3. Long-term survival after radiotherapy alone: Radiation Therapy Oncology Group prostate cancer trials
4. Bicalutamide ('Casodex') 150 mg monotherapy compared with castration in patients with non-metastatic locally advanced prostate cancer: 6.3 Years' follow-up
5. The bicalutamide early prostate cancer program. Demography
6. Tamoxifen for early breast cancer: An overview of the randomised trials
7. Bicalutamide ('Casodex') 150 mg as immediate therapy either alone or as adjuvant to standard care in patients with localized or locally advanced prostate cancer: First analysis of the Early Prostate Cancer program 2002
8. Bicalutamide (Casodex) 150 mg as immediate therapy in patients with localized or locally advanced prostate cancer significantly reduces the risk of disease progression
9. Combined orchiectomy and external radiotherapy versus radiotherapy alone for nonmetastatic prostate cancer with or without pelvic lymph node involvement: A prospective randomized study
10. Improved survival in patients with locally advanced prostate cancer treated with radiotherapy and goserelin
11. Long term results of immediate adjuvant hormonal therapy with goserelin in patients with locally advanced prostate cancer treated with radiotherapy - A phase III EORTC study
12. Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadectomy in men with node-positive prostate cancer
13. Updated results of the phase III Radiation Therapy Oncology Group (RTOG) trial 85-31 evaluating the potential benefit of androgen suppression following standard radiation therapy for unfavorable prognosis carcinoma of the prostate
14. Prostate specific antigen doubling time and disease relapse after radiotherapy for prostate cancer
15. Immediate versus deferred treatment for advanced prostatic cancer: Initial results of the Medical Research Council Trial
16. Immediate versus deferred hormone treatment for prostate cancer: How safe is androgen deprivation?
17. A structured debate: Immediate versus deferred androgen suppression in prostate cancer-evidence for deferred treatment
18. Deoxyribonucleic acid ploidy of core biopsies and metastatic lymph nodes of prostate cancer patients: Impact on time to progression
19. Gynecomastia in patients with prostate cancer: A review of treatment options